According to KFF’s research, the new Trump executive order on small molecule drugs could lead to higher Medicare prescription drug prices and potentially higher Medicare Part D premiums.

The Medicare Rights Center reports that President Trump’s executive order on prescription drug pricing supports key drug industry efforts to weaken the Inflation Reduction Act’s (IRA) Medicare negotiation program, putting Medicare and beneficiary savings at risk.

You won’t want to miss these changes announced by CMS. Plus, insights from Marcia Mantell.